Abstract

Induced pluripotent stem cells (iPSCs) are suitable for studying mitochondrial diseases caused by mitochondrial DNA (mtDNA) mutations. Here, we generated iPSCs from a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with the m.13513G>A mutation. The patient’s dermal fibroblasts were reprogrammed, and we established two iPSC clones with and without mutant mtDNA. Furthermore, we tried to decrease mutant mtDNA level in iPSCs using transcription activator-like effector nucleases (TALENs). We originally engineered platinum TALENs, which were transported into mitochondria, recognized the mtDNA sequence including the m.13513 position, and preferentially cleaved G13513A mutant mtDNA (G13513A-mpTALEN). The m.13513G>A heteroplasmy level in MELAS-iPSCs was decreased in the short term by transduction of G13513A-mpTALEN. Our data demonstrate that this mtDNA-targeted nuclease would be a powerful tool for changing the heteroplasmy level in heteroplasmic iPSCs, which could contribute to elucidation of the pathological mechanisms of mitochondrial diseases caused by mtDNA mutations.

Highlights

  • Induced pluripotent stem cells are suitable for studying mitochondrial diseases caused by mitochondrial DNA mutations

  • We determined the percentage of G13513A mutant mitochondrial DNA (mtDNA) in Induced pluripotent stem cells (iPSCs) at passage (p) 5 by an allele refractory mutation system (ARMS)-based quantitative PCR (qPCR) method (Figure S1)

  • The #61-iPSC clone, which only possessed G13513A mutant mtDNA among all iPSC clones generated by Sendai virus (Figure S1), could not be expanded after passage 5

Read more

Summary

Introduction

Induced pluripotent stem cells (iPSCs) are suitable for studying mitochondrial diseases caused by mitochondrial DNA (mtDNA) mutations. Somatic cells can be directly reprogrammed using defined genetic factors to yield induced pluripotent stem cells (iPSCs), which have the capacity to differentiate into all types of somatic cells[4] This technology allows us to create patient-specific pluripotent stem cells that retain the contents of the patient’s cells, including mtDNA. Programmable nucleases, including zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9), produce site-specific double-strand breaks (DSBs), which enhance the efficiency of targeted mutagenesis[5]. These nucleases (ZFN and TALEN) have recently shown the www.nature.com/scientificreports/. We demonstrated a shift of m.13513G>A heteroplasmy level in MELAS-iPSCs by TALEN

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call